多发性骨髓瘤的免疫治疗简述

Brief of immunotherapy for multiple myeloma

多发性骨髓瘤(multiple myeloma,MM)是血液系统的第二大恶性肿瘤,它的发病率在癌症中占1%,在血液系统恶性疾病中占10%。随着蛋白酶体抑制剂和免疫调节类的药物在临床中投入使用,该病的预后已在很大程度上得到了提高。近年来人们对MM的免疫治疗一直在进行不断的研究,也取得了一定的进展。在此我们主要对免疫调节剂、单克隆抗体、免疫监测点抑制剂等多发性骨髓瘤近年来的免疫治疗方法进行综述。

Multiple myeloma is the second most common hematologic malignancy,it＇s incidence rate accounts for about 1% of new cancers and 10% of all hematological malignancies. The treatment of this disease had been changed considerably with the introduction to the clinical practice of novel agents such as proteasome inhibitors and immuno- modulatory drugs. Many of these treatments are under clinical development and have already started providing encour-aging results. In this article,we discussed development and technological innovation of immunomodulatory drugs, anti- body therapies,immune checkpoint inhibitors, ere and summarize the major approaches in myeloma immunotherapies.